Mesa Laboratories, Inc. (NASDAQ:MLAB) Announces Quarterly Earnings Results

Mesa Laboratories, Inc. (NASDAQ:MLAB) posted its quarterly earnings results on Monday, July 31st. The medical instruments supplier reported $0.39 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.56 by $0.17, Bloomberg Earnings reports. Mesa Laboratories had a net margin of 11.31% and a return on equity of 16.58%. The firm had revenue of $22.67 million for the quarter, compared to analysts’ expectations of $22.90 million.

Shares of Mesa Laboratories (NASDAQ:MLAB) opened at 129.98 on Friday. The stock has a market cap of $488.46 million, a P/E ratio of 46.72 and a beta of 0.46. Mesa Laboratories has a 12 month low of $103.29 and a 12 month high of $169.80. The stock has a 50 day moving average price of $142.50 and a 200 day moving average price of $136.41.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Thursday, August 31st will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.49%. The ex-dividend date is Tuesday, August 29th. Mesa Laboratories’s dividend payout ratio (DPR) is presently 22.94%.

MLAB has been the subject of a number of research reports. Zacks Investment Research raised Mesa Laboratories from a “hold” rating to a “buy” rating and set a $159.00 price target for the company in a research report on Tuesday, June 13th. BidaskClub downgraded Mesa Laboratories from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th. Finally, TheStreet downgraded Mesa Laboratories from a “b” rating to a “c+” rating in a research report on Monday, July 31st.

COPYRIGHT VIOLATION WARNING: This story was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at

In other Mesa Laboratories news, insider Glenn E. Adriance sold 4,000 shares of the stock in a transaction on Friday, June 9th. The shares were sold at an average price of $148.98, for a total transaction of $595,920.00. Following the transaction, the insider now directly owns 10,000 shares of the company’s stock, valued at $1,489,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director H Stuart Campbell sold 608 shares of the stock in a transaction on Friday, August 11th. The stock was sold at an average price of $134.08, for a total transaction of $81,520.64. Following the transaction, the director now directly owns 45,368 shares in the company, valued at $6,082,941.44. The disclosure for this sale can be found here. Insiders have sold 21,760 shares of company stock worth $3,078,708 over the last three months. Company insiders own 17.00% of the company’s stock.

About Mesa Laboratories

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Earnings History for Mesa Laboratories (NASDAQ:MLAB)

What are top analysts saying about Mesa Laboratories Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mesa Laboratories Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit